News & Events
October 9, 2019
On September 25th, the FDA published a Personal Viewpoint in the American Journal of Transplantation
This Personal Viewpoint is in response to a whitepaper published by the TTC titled “The Importance of Drug Safety and Tolerability in the Development of New Immunosuppressive Therapy for Transplant Recipients”.
This article provides a FDA perspective on the whitepaper, the overall TTC effort, and public-private partnerships with authors from the Office of New Drugs, Office of Translational Sciences, and Clinical Outcome Assessment staff in CDER.